Omega-3 supplementation associated with improved parent-rated executive function in youth with mood disorders

secondary analyses of the omega 3 and therapy (OATS) trials

Anthony T. Vesco, Andrea Young, L. Eugene Arnold, Mary A. Fristad

Research output: Contribution to journalArticle

Abstract

Background: Improvements in executive functioning (EF) may lead to improved quality of life and lessened functional impairment for children with mood disorders. The aim was to assess the impact of omega-3 supplementation (Ω3) and psychoeducational psychotherapy (PEP), each alone and in combination, on EF in youth with mood disorders. We completed secondary analyses of two randomized controlled trials (RCTs) of Ω3 and PEP for children with depression and bipolar disorder. Methods: Ninety-five youths with depression or bipolar disorder not otherwise specified/cyclothymic disorder were randomized in 12-week RCTs. Two capsules (Ω3 or placebo) were given twice daily (1.87 g Ω3 total daily, mostly eicosapentaenoic acid). Families randomized to PEP participated in twice-weekly 50-min sessions. Analyses assess impact of interventions on the Behavior Rating Inventory of Executive Functioning (BRIEF) parent-report Global Executive Composite (GEC) and two subscales, Behavior Regulation (BRI) and Metacognition (MI) Indices. Intent-to-treat repeated measures ANOVAs, using multiple imputation for missing data, included all 95 randomized participants. Trials were registered with www.clinicaltrials.gov, NCT01341925 & NCT01507753. Results: Participants receiving Ω3 (aggregating combined and monotherapy) improved significantly more than aggregated placebo on GEC (p =.001, d =.70), BRI (p =.004, d =.49), and MI (p =.04, d =.41). Ω3 alone (d =.49) and combined with PEP (d =.67) each surpassed placebo on GEC. Moderation by attention-deficit/hyperactivity disorder (ADHD) comorbidity was nonsignificant although those with ADHD showed nominally greater gains. PEP monotherapy had negligible effect. Conclusions: Decreased impairment in EF was associated with Ω3 supplementation in youth with mood disorders. Research examining causal associations of Ω3, EF, and mood symptoms is warranted.

Original languageEnglish (US)
Pages (from-to)628-636
Number of pages9
JournalJournal of Child Psychology and Psychiatry and Allied Disciplines
Volume59
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Executive Function
Mood Disorders
Psychotherapy
Placebos
Attention Deficit Disorder with Hyperactivity
Bipolar Disorder
Cyclothymic Disorder
Randomized Controlled Trials
Depression
Therapeutics
Eicosapentaenoic Acid
Capsules
Comorbidity
Analysis of Variance
Quality of Life
Equipment and Supplies
Research
Metacognition

Keywords

  • bipolar disorder
  • depression
  • nutrition
  • psychotherapy
  • School children

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Cite this

@article{5b507d79a99447d08642855a9b54607c,
title = "Omega-3 supplementation associated with improved parent-rated executive function in youth with mood disorders: secondary analyses of the omega 3 and therapy (OATS) trials",
abstract = "Background: Improvements in executive functioning (EF) may lead to improved quality of life and lessened functional impairment for children with mood disorders. The aim was to assess the impact of omega-3 supplementation (Ω3) and psychoeducational psychotherapy (PEP), each alone and in combination, on EF in youth with mood disorders. We completed secondary analyses of two randomized controlled trials (RCTs) of Ω3 and PEP for children with depression and bipolar disorder. Methods: Ninety-five youths with depression or bipolar disorder not otherwise specified/cyclothymic disorder were randomized in 12-week RCTs. Two capsules (Ω3 or placebo) were given twice daily (1.87 g Ω3 total daily, mostly eicosapentaenoic acid). Families randomized to PEP participated in twice-weekly 50-min sessions. Analyses assess impact of interventions on the Behavior Rating Inventory of Executive Functioning (BRIEF) parent-report Global Executive Composite (GEC) and two subscales, Behavior Regulation (BRI) and Metacognition (MI) Indices. Intent-to-treat repeated measures ANOVAs, using multiple imputation for missing data, included all 95 randomized participants. Trials were registered with www.clinicaltrials.gov, NCT01341925 & NCT01507753. Results: Participants receiving Ω3 (aggregating combined and monotherapy) improved significantly more than aggregated placebo on GEC (p =.001, d =.70), BRI (p =.004, d =.49), and MI (p =.04, d =.41). Ω3 alone (d =.49) and combined with PEP (d =.67) each surpassed placebo on GEC. Moderation by attention-deficit/hyperactivity disorder (ADHD) comorbidity was nonsignificant although those with ADHD showed nominally greater gains. PEP monotherapy had negligible effect. Conclusions: Decreased impairment in EF was associated with Ω3 supplementation in youth with mood disorders. Research examining causal associations of Ω3, EF, and mood symptoms is warranted.",
keywords = "bipolar disorder, depression, nutrition, psychotherapy, School children",
author = "Vesco, {Anthony T.} and Andrea Young and Arnold, {L. Eugene} and Fristad, {Mary A.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1111/jcpp.12830",
language = "English (US)",
volume = "59",
pages = "628--636",
journal = "Journal of Child Psychology and Psychiatry and Allied Disciplines",
issn = "0021-9630",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Omega-3 supplementation associated with improved parent-rated executive function in youth with mood disorders

T2 - secondary analyses of the omega 3 and therapy (OATS) trials

AU - Vesco, Anthony T.

AU - Young, Andrea

AU - Arnold, L. Eugene

AU - Fristad, Mary A.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background: Improvements in executive functioning (EF) may lead to improved quality of life and lessened functional impairment for children with mood disorders. The aim was to assess the impact of omega-3 supplementation (Ω3) and psychoeducational psychotherapy (PEP), each alone and in combination, on EF in youth with mood disorders. We completed secondary analyses of two randomized controlled trials (RCTs) of Ω3 and PEP for children with depression and bipolar disorder. Methods: Ninety-five youths with depression or bipolar disorder not otherwise specified/cyclothymic disorder were randomized in 12-week RCTs. Two capsules (Ω3 or placebo) were given twice daily (1.87 g Ω3 total daily, mostly eicosapentaenoic acid). Families randomized to PEP participated in twice-weekly 50-min sessions. Analyses assess impact of interventions on the Behavior Rating Inventory of Executive Functioning (BRIEF) parent-report Global Executive Composite (GEC) and two subscales, Behavior Regulation (BRI) and Metacognition (MI) Indices. Intent-to-treat repeated measures ANOVAs, using multiple imputation for missing data, included all 95 randomized participants. Trials were registered with www.clinicaltrials.gov, NCT01341925 & NCT01507753. Results: Participants receiving Ω3 (aggregating combined and monotherapy) improved significantly more than aggregated placebo on GEC (p =.001, d =.70), BRI (p =.004, d =.49), and MI (p =.04, d =.41). Ω3 alone (d =.49) and combined with PEP (d =.67) each surpassed placebo on GEC. Moderation by attention-deficit/hyperactivity disorder (ADHD) comorbidity was nonsignificant although those with ADHD showed nominally greater gains. PEP monotherapy had negligible effect. Conclusions: Decreased impairment in EF was associated with Ω3 supplementation in youth with mood disorders. Research examining causal associations of Ω3, EF, and mood symptoms is warranted.

AB - Background: Improvements in executive functioning (EF) may lead to improved quality of life and lessened functional impairment for children with mood disorders. The aim was to assess the impact of omega-3 supplementation (Ω3) and psychoeducational psychotherapy (PEP), each alone and in combination, on EF in youth with mood disorders. We completed secondary analyses of two randomized controlled trials (RCTs) of Ω3 and PEP for children with depression and bipolar disorder. Methods: Ninety-five youths with depression or bipolar disorder not otherwise specified/cyclothymic disorder were randomized in 12-week RCTs. Two capsules (Ω3 or placebo) were given twice daily (1.87 g Ω3 total daily, mostly eicosapentaenoic acid). Families randomized to PEP participated in twice-weekly 50-min sessions. Analyses assess impact of interventions on the Behavior Rating Inventory of Executive Functioning (BRIEF) parent-report Global Executive Composite (GEC) and two subscales, Behavior Regulation (BRI) and Metacognition (MI) Indices. Intent-to-treat repeated measures ANOVAs, using multiple imputation for missing data, included all 95 randomized participants. Trials were registered with www.clinicaltrials.gov, NCT01341925 & NCT01507753. Results: Participants receiving Ω3 (aggregating combined and monotherapy) improved significantly more than aggregated placebo on GEC (p =.001, d =.70), BRI (p =.004, d =.49), and MI (p =.04, d =.41). Ω3 alone (d =.49) and combined with PEP (d =.67) each surpassed placebo on GEC. Moderation by attention-deficit/hyperactivity disorder (ADHD) comorbidity was nonsignificant although those with ADHD showed nominally greater gains. PEP monotherapy had negligible effect. Conclusions: Decreased impairment in EF was associated with Ω3 supplementation in youth with mood disorders. Research examining causal associations of Ω3, EF, and mood symptoms is warranted.

KW - bipolar disorder

KW - depression

KW - nutrition

KW - psychotherapy

KW - School children

UR - http://www.scopus.com/inward/record.url?scp=85047515684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047515684&partnerID=8YFLogxK

U2 - 10.1111/jcpp.12830

DO - 10.1111/jcpp.12830

M3 - Article

VL - 59

SP - 628

EP - 636

JO - Journal of Child Psychology and Psychiatry and Allied Disciplines

JF - Journal of Child Psychology and Psychiatry and Allied Disciplines

SN - 0021-9630

IS - 6

ER -